Molecular formula:C221H342N46O68
Molecular weight: 4731.33
Patent period: Compound: 2026 Composition: 2029
Dositive specifications:–
Injection (type II diabetes, OZEMPIC): —
Oral tablets: —
Injection : —
Molecular formula:C221H342N46O68
Molecular weight: 4731.33
Patent period: Compound: 2026 Composition: 2029
Dositive specifications:–
Injection (type II diabetes, OZEMPIC): —
Oral tablets: —
Injection : —
Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775nM, respectively. Retarutide can be used for obesity research.
ACTIONS | — |
---|---|
CAS NO. | 2381089-83-2 |
FORMULA | C221H342N46O68 |
M. WT | 4731.33 |
PURITY | > 98% |
SYNONYMS | LY3437943 |
STORAGE |
— |